Statins anticancer targeted delivery systems: re-purposing an old molecule
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Objectives: Exploring the use of statins as anticancer agents and exploiting different drug delivery systems in targeting these molecules to cancerous sites. Literature review was performed to investigate the use of statins in cancer treatment in one hand, and the different pharmaceutical approaches to deliver and target these drugs to their site of action. Key findings: Statins were used for decades as antihypercholestrolemic drugs but recently have been proven potential for broad anticancer activities. The incorporation of statins in nanoparticulate drug delivery systems not only augmented the cytotoxicity of statins but also overcame the resistance of cancerous cells against the traditional chemotherapeutic agents. Statins-loaded nanoparticles could be easily tampered to target the cancerous cells and consequently minimal drug amount could be utilized. Summary: This review reconnoitered the different endeavors to incorporate statins in various nanoparticles and summarized the successful effects in targeting cancerous cells and reducing their proliferation without the side effects of commonly used chemotherapeutic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biomolecular coronas provide the biological identity of nanosized materials
Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.207 · Cited by 3,017
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
PLEIOTROPIC EFFECTS OF STATINS
Liao, J. K., & Laufs, U. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.45.120403.095748 · Cited by 1,994
Structural mechanism for statin inhibition of HMG-CoA reductase
Istvan, E. S., & Deisenhofer, J. (2001) · Science · doi:10.1126/science.1059344 · Cited by 1,644 · cited 1×
“All statins possess a 3-hydroxy-3-methylglutaryl (HMG)–like moiety that has high affinity to HMG-CoA reductase so sterically block this enzyme thereby inhibiting the production of mevalonate, the first step in the cholesterol biosynthesis.([6]) Moreover, statins are used in the treatment of aortic aneurysms,([7]) infl…”
BackgroundDrug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Synthetic genetic polymers capable of heredity and evolution
Pinheiro, V. B., Taylor, A. I., Cozens, C., Abramov, M., Renders, M., Zhang, S., Chaput, J. C., Wengel, J., Peak-Chew, S.-Y., McLaughlin, S. H., et al. (2012) · Science · doi:10.1126/science.1217622 · Cited by 730
Amine coupling through EDC/NHS: a practical approach
Fischer, M. J. E. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-670-2_3 · Cited by 492 · cited 1×
“Biotin is commonly used owing to its small size so not affect the function of the ligand.([147]) This design was commonly and preferentially used for antibodies, peptides and aptamers.”
Background
Cited by
Simmons, R. K., Griffin, S. J., Lauritzen, T., & Sandbæk, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4299-y · Cited by 69
“We also observed lower rates of cancer incidence in the screening group, which might be linked to changes in health behaviour and prescribing [26].”
BackgroundApplication of nanotechnology to improve the therapeutic benefits of statins
Korani, S., Korani, M., Bahrami, S., Johnston, T. P., Butler, A. E., Banach, M., & Sahebkar, A. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.023 · Cited by 51
Repurposing drugs targeting metabolic diseases for cancer therapeutics
Pillai U, J., Ray, A., Maan, M., & Dutta, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103684 · Cited by 31
An overview on nanoplatforms for statins delivery: Perspectives for safe and effective therapy
Etemad, L., Salmasi, Z., Moosavian Kalat, S. A., Moshiri, M., Zamanian, J., Kesharwani, P., & Sahebkar, A. (2023) · Environmental Research · doi:10.1016/j.envres.2023.116572 · Cited by 18
Metadata
- Authors
- Safwat, S., Ishak, R. A., Hathout, R. M., & Mortada, N. D.
- Venue
- Journal of Pharmacy and Pharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06-01
- Volume
- 69
- Issue
- 6
- Pages
- 613-624
- ISSN
- 0022-3573 (ISSN-L)
- 2042-7158
- OpenAlex
- W2592121434
- Cited by
- 48
- References
- 7
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.